Expansion of intratumoral hemorrhage in a patient with macroprolactinoma treated with cabergoline

Endocrinologist

Volumn 14, Issue 3, 2004, Pages 126-128

  Ishay, Avraham ^a   Levahar, Pierre ^a   Qupty, Ghali ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cabergoline; Hemorrhage; Pituitary adenoma; Prolactin

Indexed keywords

BROMOCRIPTINE; CABERGOLINE;

ADULT; AMENORRHEA; ARTICLE; BITEMPORAL HEMIANOPIA; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FEMALE; GALACTORRHEA; HEADACHE; HEMIANOPIA; HUMAN; HYPOPHYSIS ADENOMA; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PROLACTINOMA; SIDE EFFECT; SYMPTOM; TRANSSPHENOIDAL SURGERY; TREATMENT FAILURE; TUMOR BLEEDING; VISUAL FIELD DEFECT;

EID: 2542488372     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000127930.93592.b2     Document Type: Article

References (20)

1. Bevans JS, Webster J, Burke CW, et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220-239.
2. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698-705.
3. Colao A, Disarno A, Landi ML, et al. Long term and low dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574-3579.
4. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331:904-909.
5. Pontikides N, Krassas GE, Nikopoulou E, et al. Cabergoline as a first line treatment in newly diagnosed macroprolactinomas. Pituitary. 2000; 2:277-281.
6. Cannavo S, Curto L, Squadrito S, et al. Cabergoline: a first choice treatment in patients with previously untreated prolactin secreting pituitary adenoma. J Endocrinol Invest. 1999;22:354-359.
7. Colao A, Disarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876-883.
8. Wakai S, Fukushima T, Teramoto A, et al. Pituitary apoplexy: its incidence and clinical significance. J Neurosurg. 1981;55:187-193.
9. Fraioli B, Esposito V, Palma L, et al. Hemorrhagic pituitary adenomas: clinicopathological features and surgical treatment. Neurosurgery. 1990; 27:741-748.
10. Youssem DM, Arrington JA, Zinreich SJ, et al. Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology. 1989;170:239-243.
11. Dallabonanzana D, Spelta B, Oppizzi G, et al. Re-enlargement of macroprolactinomas during bromocriptine therapy: report of two cases. J Endocrinol Invest. 1983;6:47-50.
12. Biller BMK, Molitch ME, Vance ML, et al. Treatment of prolactin secreting macroadenomas with the once weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996;81:2238-2243.
13. Kupersmith MJ, Kleinberg D, Marren FA, et al. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery. 1989;24:417-423.
14. Cannavo S, Bartolone L, Blandino A, et al. Shrinkage of a prolactin secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Investig. 1999;22:306-309.
15. Wallace EA, Holdaway IM. Treatment of macroprolactinomas at Auckland hospital 1975-1991. N Z Med J. 1995;108:50-52.
16. Perrin G, Treluyer C, Trouillas J, et al. Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas. Pathol Res Pract. 1991;187:587-592.
17. Pinto G, Zerah M, Trivin C, et al. Pituitary apoplexy in an adolescent with prolactin-secreting adenoma. Horm Res. 1995;50:38-41.
18. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemias: a study of 455 patients. J Clin Endocrinol Metab. 1999;84:2518-2522.
19. Ferrari CI, Abs R, Bevans JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol. 1997;46:409-413.
20. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247-2252.